Calithera Biosciences (CALA) Competitors $0.0020 0.00 (0.00%) As of 06/10/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CALA vs. EVLO, SCPS, CMRA, GNCAQ, GNCA, SMFL, ARDS, STAB, AMPE, and CLVRShould you be buying Calithera Biosciences stock or one of its competitors? The main competitors of Calithera Biosciences include Evelo Biosciences (EVLO), Scopus BioPharma (SCPS), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Smart for Life (SMFL), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), and Clever Leaves (CLVR). These companies are all part of the "pharmaceutical products" industry. Calithera Biosciences vs. Its Competitors Evelo Biosciences Scopus BioPharma Comera Life Sciences Genocea Biosciences Genocea Biosciences Smart for Life Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals Clever Leaves Calithera Biosciences (NASDAQ:CALA) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Do insiders & institutionals believe in CALA or EVLO? 0.3% of Evelo Biosciences shares are owned by institutional investors. 6.6% of Calithera Biosciences shares are owned by insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, CALA or EVLO? Calithera Biosciences has a beta of -2.56, suggesting that its stock price is 356% less volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Which has stronger valuation and earnings, CALA or EVLO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalithera BiosciencesN/AN/A-$39.65MN/AN/AEvelo BiosciencesN/AN/A-$114.53MN/AN/A Does the MarketBeat Community prefer CALA or EVLO? Calithera Biosciences received 171 more outperform votes than Evelo Biosciences when rated by MarketBeat users. However, 60.50% of users gave Evelo Biosciences an outperform vote while only 55.09% of users gave Calithera Biosciences an outperform vote. CompanyUnderperformOutperformCalithera BiosciencesOutperform Votes34155.09% Underperform Votes27844.91% Evelo BiosciencesOutperform Votes17060.50% Underperform Votes11139.50% Is CALA or EVLO more profitable? Company Net Margins Return on Equity Return on Assets Calithera BiosciencesN/A N/A N/A Evelo Biosciences N/A N/A N/A Does the media favor CALA or EVLO? In the previous week, Evelo Biosciences had 1 more articles in the media than Calithera Biosciences. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Calithera Biosciences. Calithera Biosciences' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score. Company Overall Sentiment Calithera Biosciences Neutral Evelo Biosciences Neutral SummaryEvelo Biosciences beats Calithera Biosciences on 4 of the 7 factors compared between the two stocks. Get Calithera Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALA vs. The Competition Export to ExcelMetricCalithera BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10K$6.85B$5.57B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.7827.1420.06Price / SalesN/A255.49419.32157.08Price / CashN/A65.8538.2534.64Price / BookN/A6.557.064.70Net Income-$39.65M$143.93M$3.23B$247.88M7 Day PerformanceN/A3.84%2.83%2.63%1 Month PerformanceN/A11.20%9.02%6.36%1 Year PerformanceN/A4.18%31.36%14.05% Calithera Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALACalithera Biosciences0.6238 of 5 stars$0.00flatN/A-90.0%$10KN/A0.0060Gap DownEVLOEvelo BiosciencesN/A$0.00+400.0%N/AN/A$38KN/A0.00120Options VolumeHigh Trading VolumeSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070SMFLSmart for LifeN/A$0.00+100.0%N/A-99.7%$6K$11.11M0.00110Positive NewsGap UpARDSAridis PharmaceuticalsN/A$0.00-66.7%N/A-99.8%$5K$3.09M0.0030Gap DownSTABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020AMPEAmpio Pharmaceuticals0.2964 of 5 stars$0.00flatN/A-97.9%$3KN/A0.0020CLVRClever LeavesN/A$0.00flatN/A-100.0%$1K$17.42M0.00560 Related Companies and Tools Related Companies EVLO Competitors SCPS Competitors CMRA Competitors GNCAQ Competitors GNCA Competitors SMFL Competitors ARDS Competitors STAB Competitors AMPE Competitors CLVR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calithera Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
